Table 3.
Two year EFS probability, relapse risk, TRM risk, and overall survival probability among patients alive and relapse-free at day 55+ by leukemia risk group, pre-HCT MRD.* The top part of the table does not take aGVHD into consideration. The lower part assesses outcome with and without aGVHD prior to day 55 and gives the outcome probabilities from day 55 to 2 years for patients alive and relapse free at day 55.
| Leukemia Risk Group | Pre-HCT MRD | N | aGVHD by day 55 | EFS probability | Relapse risk | TRM risk | Survival probability | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| High risk CR1 or CR2 | <0.1% | 64 | 47.0% | (34.4–58.7) | 30.0% | (19.0–41.7) | 23.0% | (13.7–33.6) | 55.1% | (41.9–66.6) | |
| High risk CR1 or CR2 | ≥0.1% | 16 | 14.6% | (3.2–34.0) | 64.5% | (34.0–83.7) | 20.9% | (6.1–41.4) | 36.3% | (13.3–60.1) | |
| Intermediate risk CR2 | <0.1% | 19 | 83.3% | (57.9–94.1) | 16.7% | (4.8–34.8) | 0.0% | – | 87.5% | (60.0–96.6) | |
|
| |||||||||||
| High risk CR1 or CR2 | <0.1% | 43 | None | 47.0% | (30.2–62.2) | 41.8% | (25.4–57.3) | 11.2% | (3.7–23.5) | 59.9% | (42.1–73.8) |
| High risk CR1 or CR2 | <0.1% | 21 | Grade I–III | 65.8% | (39.5–82.8) | 17.0% | (4.3–37.0) | 17.2% | (4.5–36.8) | 65.6% | (39.1–82.7) |
| High risk CR1 or CR2 | ≥0.1% | 11 | None | 11.7% | (1.8–31.7) | 73.2% | (36.9–90.7) | 15.1% | (3.2–35.4) | 40.8% | (13.5–66.9) |
| High risk CR1 or CR2 | ≥0.1% | 5 | Grade I–III | 36.5% | (1.0–80.4) | 46.7% | (1.1–87.9) | 16.8% | (3.7–38.1) | 30.1% | (1.0–73.3) |
| Intermediate risk CR2 | <0.1% | 8 | None | 72.8% | (30.6–91.8) | 27.2% | (5.8–55.2) | – | 71.4% | (29.9–91.1) | |
| Intermediate risk CR2 | <0.1% | 11 | Grade I–III | 90.6% | (50.8–98.6) | 9.4% | (0.7–32.8) | – | 100.0% | (.–100.0) | |
*
Grade IV aGVHD outcomes: 1 IR CR2, MRD <0.1% (1 died); 4 H CR2, MRD <0.1% (4 died), 2 HR CR2, MRD not done (1 died)